- Home
- ALLO vs MLAC Comparison
ALLO vs MLAC Comparison
Compare ALLO & MLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- MLAC
- Stock Information
- Founded
- ALLO 2017
- MLAC 2024
- Country
- ALLO United States
- MLAC United States
- Employees
- ALLO N/A
- MLAC N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- MLAC
- Sector
- ALLO Health Care
- MLAC
- Exchange
- ALLO Nasdaq
- MLAC NYSE
- Market Cap
- ALLO 371.8M
- MLAC 314.4M
- IPO Year
- ALLO 2018
- MLAC 2024
- Fundamental
- Price
- ALLO $1.11
- MLAC $10.16
- Analyst Decision
- ALLO Strong Buy
- MLAC
- Analyst Count
- ALLO 10
- MLAC 0
- Target Price
- ALLO $8.90
- MLAC N/A
- AVG Volume (30 Days)
- ALLO 4.1M
- MLAC 90.6K
- Earning Date
- ALLO 05-13-2025
- MLAC 01-01-0001
- Dividend Yield
- ALLO N/A
- MLAC N/A
- EPS Growth
- ALLO N/A
- MLAC N/A
- EPS
- ALLO N/A
- MLAC N/A
- Revenue
- ALLO N/A
- MLAC N/A
- Revenue This Year
- ALLO N/A
- MLAC N/A
- Revenue Next Year
- ALLO $9.07
- MLAC N/A
- P/E Ratio
- ALLO N/A
- MLAC $414.52
- Revenue Growth
- ALLO N/A
- MLAC N/A
- 52 Week Low
- ALLO $0.86
- MLAC $9.94
- 52 Week High
- ALLO $3.78
- MLAC $10.19
- Technical
- Relative Strength Index (RSI)
- ALLO 38.30
- MLAC N/A
- Support Level
- ALLO $1.07
- MLAC N/A
- Resistance Level
- ALLO $1.15
- MLAC N/A
- Average True Range (ATR)
- ALLO 0.14
- MLAC 0.00
- MACD
- ALLO -0.01
- MLAC 0.00
- Stochastic Oscillator
- ALLO 27.17
- MLAC 0.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About MLAC MOUNTAIN LAKE ACQUISITION CORP
Mountain Lake Acquisition Corp is a blank check company.